Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

the Effect of Cerebrolysin on Physical and Mental Functions of Down Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04751136
Recruitment Status : Completed
First Posted : February 11, 2021
Last Update Posted : February 11, 2021
Information provided by (Responsible Party):
Yahya Wahba, Mansoura University Children Hospital

Brief Summary:

Down syndrome is a genetic disorder that causes delay in both physical growth and mental development. It is the most frequently reported chromosomal abnormality and the most common genetic syndrome.

Down syndrome is caused by trisomy of all or part of the genetic material of human chromosome 21. It is now estimated that 94% of individuals with Down syndrome have an extra chromosome 21 as a result of meiotic non-disjunction, or the abnormal segregation of chromosomes during maternal gamete formation and of the remaining 5%, less than 1% is due to somatic mosaicism and the rest is due to chromosome 21 translocations.

The estimated incidence of Down syndrome is between 1 / 1,000 to 1 / 1,100 live births worldwide. In Egypt, the incidence of Down syndrome has been reported to be 1 / 1000 live births.

Down syndrome is characterized by intellectual disability, short stature, distinctive facial characters and a number of co-morbidities including cardiac and digestive anomalies, thyroid problems, and childhood leukemia.

Down syndrome infants will likely experience delays in certain areas and aspects of development. However, they will achieve all of the same milestones as other normal children, just on their own timetable.

According to recent studies, the Down syndrome behavioral phenotype includes relative strengths in some aspects of visuo-spatial processing and social functioning as well as relative deficits in verbal processing. Language has been described as a "major area of deficit" in Down syndrome individuals with particular difficulties manifested in expressive language.

Due to this high incidence of Down syndrome in Egypt and the associated co-morbidities, governmental care directed to this syndrome and other handicapping conditions has increased tremendously in the past few years to the extent that Down syndrome phenotype has become a phobia and many parents and/or physicians referred normal babies for karyotype due to either suspicion of chromosomal anomalies or just for reassurance of their parents.

Although there has been enormous progress in the management of the physical aspects of Down syndrome e.g. repair of heart defects, little advancement has been made to prevent deterioration of cognitive function in these individuals. As a result, the dramatic increase in life expectancy of children with Down syndrome in the past few decades has not been paralleled with concurrent treatment for cognitive disabilities. Therefore, it has remained the most common cause of cognitive dysfunction in children.

The pathogenesis of cognitive deficits and motor disabilities in Down syndrome individuals can be attributed to diminished number and size of neuronal density, progressive neuronal degeneration, impairment of neurogenesis, and reduction in dendrite formation as well as spine density which results in disruption of synaptic function and plasticity. Therefore, many of these individuals develop increasing problems with learning and memory in later life.

Cerebrolysin® is a neurotrophic peptidergic mixture isolated from pig brain. It is produced by standardized enzymatic breakdown of lipid-free porcine brain proteins .

It acts similar to endogenous neurotrophic factors in the form of promoting neuronal sprouting, stimulating neurogenesis, enhancing neuronal plasticity, and improving learning and memory.

Several studies demonstrated that Cerebrolysin® can be used safely in the management of children with any of the following medical conditions: minimal cerebral dysfunction, resistant forms of nocturnal enuresis, neurosensory hypoacusis, attention deficit hyperkinetic disorder, autism and Asperger syndrome.

The overall aim of the study is to assess the effect of Cerebrolysin® on neurocognitive development of infants with Down syndrome.

Condition or disease Intervention/treatment Phase
Down Syndrome Drug: cerebrolysin Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 64 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Phase (2) Clinical Trial Studying the Effect of Cerebrolysin on Physical and Mental Functions of Down Syndrome
Actual Study Start Date : September 30, 2016
Actual Primary Completion Date : February 28, 2019
Actual Study Completion Date : August 30, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Down Syndrome

Arm Intervention/treatment
Active Comparator: Intervention Arm
infants were given Cerebrolysin®, manufactured by Neuro Pharma Gmbh, in a dose of 0.1 ml / kg body weight once weekly intramuscular injection for 12 month (total of 48 injections).
Drug: cerebrolysin
Infants of the treatment group were given Cerebrolysin in a dose of 0.1 ml / kg body weight once weekly intramuscular injection for 12 month (total of 48 injections).Each selected infant, in both treatment and control group, was assessed as regard: Socioeconomic status, Nutritional status and feeding practice, assessed for neurocognitive development

No Intervention: Non-intervention Arm
No medication was given

Primary Outcome Measures :
  1. Rate of neurocognitive development [ Time Frame: Time frame: 12 month ]
    We measure neurocognitive development using Bayley Scales of infant and toddler development®, 3rd Edition (BSID -III®) for infants of both groups, after 6 and 12 month of Cerebrolysin® injection. This scale assesses 5 subsets: receptive communication, expressive communication, fine motor, gross motor and cognitive development. Tests are implemented using the child's age (in months) to determine the starting test item for each subtest, and applying the reversal and discontinue rules. Then, the raw score is calculated for each subset as the number of test items that precede the starting item plus the number of items completed by the infant. Finally, test raw scores are recorded on standard record forms. Then, Z scores of scores are calculated according to USA norms. These calculated z scores are used as a standard to compare the rate of development for each subset.

Secondary Outcome Measures :
  1. Number of participants with side effects of cerebrolysin [ Time Frame: Time frame: 12 month ]
    We measure side effects that might occur during Cerebrolysin® therapy (one course with total of 48 injections).This is done, with every follow up visit, by physical examination of infants, and history taking from parents and care givers about development of irritability or convulsions during Cerebrolysin® therapy.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Months to 7 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Infants were confirmed to have Down syndrome of non disjunction genotype.
  • Age was around 6 month, at time of recruitment.
  • Legal guardians accepted to participate in the study and sign the informed consent.

Exclusion Criteria:

  • Patients having uncontrolled hypothyroidism
  • Patients with brain malformations other than the expected in infant with Down syndrome.
  • Patients with hearing and / or vision impairments.
  • severe congenital heart disease
  • Patients having contraindications for the use of Cerebrolysin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04751136

Layout table for location information
Mansoura University Children Hospital
Mansourah, Dakahlia, Egypt, 35516
Sponsors and Collaborators
Mansoura University Children Hospital
Layout table for investigator information
Study Director: Sohier Yahia, MD Mansoura University Children Hospital

Layout table for additonal information
Responsible Party: Yahya Wahba, Assistant Professor of Pediatrics and Genetics, Mansoura University Children Hospital Identifier: NCT04751136    
Other Study ID Numbers: MansouraUCH1
First Posted: February 11, 2021    Key Record Dates
Last Update Posted: February 11, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Down Syndrome
Pathologic Processes
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs
Nootropic Agents